{
  "CAALLF01_protocole_V6_20181211": {
    "ALL": "Acute Lymphoblastic Leukemia",
    "API": "Active Pharmaceutical Ingredient",
    "CMO": "Contract Manufacturing Organization",
    "CNS": "Central Nervous System",
    "CR": "complete remission",
    "DFS": "disease-free survival",
    "DNR": "daunorubicine",
    "DEX": "dexamethasone",
    "EFS": "event-free survival",
    "GMP": "Good Manufacturing Practices",
    "HD-MTX": "high-dose methotrexate",
    "HR": "High Risk",
    "HSCT": "Hematopietic Stem Cell Transplantation",
    "IM": "intramuscular",
    "IMP": "Investigational Medicinal Product",
    "IT": "intrathecal injection",
    "IV": "intravenous infusion",
    "MR": "Medium Risk",
    "MRD": "minimal residual disease",
    "MTX": "methotrexate",
    "NCI": "National Cancer Institute",
    "NCI-CTCAE": "National Cancer Institute Common Terminology Criteria for Adverse Events",
    "OS": "overall survival",
    "PEG": "pegaspargase",
    "PNN": "neutrophils",
    "PRED": "prednisone",
    "SAE": "severe adverse event",
    "SR": "Standard Risk",
    "TP": "Time Point",
    "TLP": "Traumatic lumbar punction",
    "VCR": "vincristine",
    "VHR": "Very High Risk",
    "WBC": "White Blood Cell Count"
  },
  "PARADISE_protocole_v7.1_20240709": {
    "LIST": "OF ABBREVIATIONS AND RELEVANT DEFINITIONS",
    "AE": "Adverse Event",
    "AR": "Adverse Reaction",
    "ASR": "Annual Safety Report",
    "CA": "Competent Authority",
    "CBC": "Complete Blood Count",
    "CD": "Crohn’s Disease",
    "CDED": "Crohn’s Disease Exclusion Diet",
    "CDAI": "Crohn’s Disease Activity Index",
    "CDEIS": "Crohn’s Disease Endoscopic Index of Severity",
    "CRA": "Clinical Research Associate",
    "CRP": "C-reactive protein",
    "CV": "Curriculum Vitae",
    "DSMB": "Data Safety Monitoring Board",
    "EEN": "Exclusive Enteral Nutrition",
    "FCP": "Faecal Calprotectin",
    "GCP": "Good Clinical Practice",
    "HBI": "Harvey-Bradshaw Index",
    "IBD": "Inflammatory Bowel Disease",
    "IBDQ": "Inflammatory Bowel Disease Questionnaire",
    "ICF": "Informed Consent Form",
    "ITT": "Intent-to-treat principle",
    "PCC": "PillCam Crohn’s Capsule",
    "PEN": "Partial Enteral Nutrition",
    "PIL": "Patient Information Letter",
    "SAP": "Statistical Analysis Plan",
    "SES-CD": "Simple Endoscopic Score for Crohn’s Disease",
    "SF16": "Short Form 16",
    "SUSAR": "Suspected Unexpected Serious Adverse Reaction",
    "WPAI": "Work Productivity Index"
  },
  "GRAALL2014_Protocol_V5.1_2018.04.09": {
    "HSCT": "Haematopoietic Stem Cell Transplantation",
    "ALAT": "Alanine-Aminotransferase",
    "IT": "Intra-thecal",
    "IUD": "Intrauterine Device",
    "IV": "Intravenous",
    "LR": "Low Risk",
    "MMolR": "Major Molecular Response",
    "LWH": "Low Weight Heparin",
    "RTC": "Reduced Toxicity Conditioning",
    "RFS": "Relapse-Free Survival",
    "RBC": "Red Blood Cells",
    "PS": "Performans Status",
    "PO": "Per Os",
    "ANC": "Polymorphonuclear",
    "SC": "SubCutaneous",
    "ALL": "Acute Lymphoblastic Leukemia",
    "ANSM": "“Agence Nationale de sécurité du ",
    "ASAT": "Aspartate Amino Transferase ",
    "AT": "Anti Thrombin ",
    "ATG": "Anti ThymoGlobulin MAC: Myelo Ablative Conditioning",
    "BID": "Twice a day ",
    "BM": "Bone Marrow MRD: Minimal Residual Disease",
    "BMI": "Body Mass Index MRI: Magnetic Resonance Imaging",
    "CIR": "Cumulative Incidence of Relapse ",
    "MTX": "Methotrexate",
    "CIV": "ContinuousIntravenous ",
    "NRM": "Non Relapse related Mortality",
    "NYHA": "New York Heart Association",
    "OS": "Overall survival",
    "CML": "ChronicMyelogenous Leukemia ",
    "CNS": "Central Nervous System ",
    "PB": "Peripheral Blood",
    "PHRC": "Programme Hospitalier",
    "CPM": "Cyclophosphamide ",
    "CPP": "Comité de Protection des Personnes de Recherche Clinique",
    "CR": "Complete Remission",
    "CRA": "Clinical Research Assistant ",
    "CRF": "Case Report Form ",
    "CSF": "Cerebro Spinal Fluid ",
    "DFS": "Disease free survival ",
    "DIVC": "Disseminated Intravascular Coagulation ",
    "DMA": "Drug Marketing Authorization ",
    "SAE": "Serious Adverse Event",
    "DNR": "Daunorubicin",
    "DVI": "Dexamethasone, Vincristine, ITK",
    "SGOT": "Serum Glutamic OxaloaceticTransferase",
    "ECG": "Electrocardiogram ",
    "SGPT": "Serum GlutamopyruvateTransferase",
    "ECOG": "Eastern Cooperative Oncology Group",
    "SIV": "Slow Intravenous",
    "FFD": "Form of Functions Delegation",
    "SPC": "Summary of Product Characteristics",
    "FFP": "Fresh Frozen Plasma ",
    "SR": "Standard Risk",
    "FGM": "France Greffe de Moelle ",
    "TBI": "Total Body Irradiation",
    "FR": "Shortening Fraction ",
    "TD": "Total Dose",
    "GCP": "Good Clinical Practice ",
    "TDM": "Tomodensitometry",
    "G-CSF": "Granulocyte colony-stimulating factor",
    "TKI": "Tyrosine Kinase Inhibitor",
    "GNB": "Gram Negative Bacteria",
    "TLP": "Traumatic Lumbar Puncture",
    "GPB": "Gram Positive Bacteria ",
    "TUA": "Temporary Usage Authorization",
    "GVH": "Graft versus Host ",
    "ULN": "Upper Limit of Normal",
    "HCR": "Hematologic Complete Remission ",
    "VCR": "Vincristine",
    "HD": "High Dose ",
    "VDS": "Vindesine",
    "HLA": "Human Leukocyte Antigen",
    "VEF": "Ventricular Ejection Fraction",
    "HR": "High Risk ",
    "VHR": "Very High Risk",
    "HSC": "Hematopoietic Stem Cells ",
    "VP-16": "Etoposide",
    "WBC": "White Blood Cells"
  },
  "RUBI_protocole_v8-0_20210519_signe": {
    "ADA": "Anti-drug antibodies",
    "ADCC": "Antibody dependent cell-mediated cytotoxicity",
    "AE": "Adverse event",
    "ALT": "Alanine amino transferase",
    "AST": "Aspartate amino transferase",
    "ATC": "Anatomical-Therapeutic-Chemical classification",
    "AUC": "Area under the curve",
    "AZA": "Azathioprine",
    "BCVA": "Best corrected visual acuity",
    "BRB": "Blood-retinal barrier",
    "BUN": "Blood urea nitrogen",
    "CBC": "Complete blood count",
    "CHO": "Chinese hamster ovary",
    "CINCA": "Chronic Infantile Neurological Cutaneous Articular",
    "CRF": "Case Report Form",
    "CSA": "Cyclosporine A",
    "CTCAE": "Common Terminology Criteria for Adverse Events",
    "EAU": "Experimental autoimmune uveitis/uveoretinitis",
    "EC": "Ethics Committee",
    "ECG":"Electrocardiogram",
    "ECL": "Electrochemiluminescence",
    "EDC": "Electronic data capture",
    "EIU": "Endotoxin-induced uveitis",
    "EMA": "European Medicines Agency",
    "ETDRS": "Early treatment diabetic retinopathy study",
    "FFA": "Fundus Fluorescein Angiography",
    "GCP": "Good Clinical Practice",
    "GLP": "Glucagon-like peptide or Good Laboratory Practice (note",
    "H1N1": "Hemagglutinin type 1 and neuramimidase type 1",
    "HIV": "Human immunodeficiency virus",
    "IC": "Half maximal inhibitory concentration",
    "ICH": "International Conference on Harmonization",
    "ID": "Identification",
    "INH": "Isonicotinylhydrazine (also known as isoniazid)",
    "IRS": "Interactive response system",
    "IUD": "Intrauterine device",
    "IUSG": "International Uveitis Study Group",
    "IV": "Intravenous",
    "KD": "Equilibrium dissociation constant",
    "MMF": "Mycophenolate mofetil",
    "MPS": "Mycophenolate sodium",
    "MRI": "Magnetic Resonance Imaging",
    "MTX": "Methotrexate",
    "NEI": "National Eye Institute",
    "NOAEL": "No-observed-adverse-effect-level",
    "OCT": "Optical coherence tomography",
    "OUD": "Occurrence of uveitic disease",
    "PBMC": "Peripheral blood mononuclear cell",
    "PD": "Pharmacodynamic",
    "PK": "Pharmacokinetic",
    "PO": "Oxygen pressure",
    "PPD": "Purified protein derivative",
    "Q4W": "Every 4 weeks",
    "QOL": "Quality of life",
    "RA": "Rheumatoid arthritis",
    "SAE": "Serious adverse event",
    "SC": "Subcutaneous",
    "SPR": "Surface Plasmon Resonance",
    "SUN": "Standardization of Uveitis Nomenclature",
    "TB": "Tuberculosis",
    "TBD": "To be determined",
    "TH1": "T helper 1 cell",
    "TH17": "T helper 17 cell",
    "TLR": "Toll-like receptor",
    "T2D": "Type 2 diabetes",
    "ULN": "Upper limit of normal",
    "WBC": "White blood cell (count)",
    "WHODD": "World Health Organization Drug",
    "WMA": "World Medical Association"
    
  },
  "D1_2023-505977-34-00_Protocol_V1.1_16102024_MSC-AT-SSC": {
    "ACR/EULAR": "American College of Rheumatology/European League Against Rheumatism",
    "AD": "Autoimmune Disease",
    "AE": "Adverse Event",
    "AHSCT": "Autologous Hematopoietic Stem Cell Transplantation",
    "BMI": "Body Mass Index",
    "CTC-AE": "NCI Common Terminology Criteria for Adverse Events",
    "CRISS": "ACR Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis",
    "DLCO": "diffusing capacity of lung for carbon monoxide",
    "EQ-5D-5L": "EuroQol 5-Dimension 5-Level",
    "FVC": "Forced Vital Capacity",
    "GMP": "Good Manufacturing Practices",
    "GRCS": "Global Rank Composite Score",
    "HRQoL": "Health-Related Quality of Life",
    "mRSS": "modified Rodnan Skin Score",
    "IV": "Intraveinous",
    "MMF": "Mycophenolate mofetil",
    "MSC": "Mesenchymal Stromal Cells",
    "MSC (AT)": "Mesenchymal Stromal Cells derived from AdiposeTissue",
    "MSC (M)": "Mesenchymal Stromal Cells derived from bone Marrow",
    "MSC (UC)": "Marrow derived Mesenchymal Stromal Cells derived from Umbilical Cord",
    "QALY": "Quality-Adjusted Life Year",
    "PFS": "Progression-Free Survival",
    "SAE": "Severe Adverse Event",
    "SAR": "Serious Adverse Reactions",
    "SHAQ": "Scleroderma-Health Assessment Questionnaire",
    "SF-36": "The Short Form (36) Health Survey",
    "SSc": "Systemic Sclerosis"
  },
  "PCL-2_protocole_v4-0_20240606": {
    "ANSM": "Agence Nationale de Sécurité des Médicaments et des Produits de santé",
    "ALT": "Alanine aminotransferase",
    "ANC": "absolute neutrophil count",
    "AST": "and aspartate aminotransferase",
    "ASCT": "autologous stem cell transplantation",
    "CBC": "Complete Blood Count",
    "CCTAE": "common toxicity criteria",
    "CPP": "Comité de Protection des Personnes",
    "CR": "Complete Response",
    "DOR": "Duration of response",
    "ECOG": "Eastern Cooperative Oncology Group",
    "EOT": "End of Treatment",
    "GI": "Gastro intestinal",
    "IMWG": "International Myeloma Working Group",
    "ISS": "International Staging System",
    "VRD": "Bortezomib-Lenalidomide-Dexamethasone",
    "MHSC": "Mobilization and harvesting stem cells",
    "MM": "multiple myeloma",
    "MRD": "minimal-residual disease",
    "NCI": "National Cancer Institute",
    "NGS": "Next-Generation Sequencing",
    "ORR": "Overall response rate",
    "OS": "Overall survival",
    "PBSC": "Peripheral Blood Hematopoietic Stem Cells",
    "PCL": "primitive plasma cell leukemia",
    "PFS": "progression-free survival",
    "SAE": "Serious Adverse Event",
    "SC": "Subcutaneous",
    "SPM": "Second primary malignancy",
    "TEAE": "Treatment Emergent Adverse Event",
    "TTP": "Time to progression",
    "ULN": "upper limit of the normal range",
    "VGPR": "Very Good Partial Response"
  },
  "CAMOVID_protocole_v6.0-20211108_signe": {
    "ACE2": "Angiotensin Converting Enzyme 2",
    "AGEPS": "Agence générale des équipements et produits de santé",
    "AE": "adverse event",
    "ANSM": "Agence nationale de sécurité du medicament et des produits de santé",
    "APHP": "Assistance Publique Hôpitaux de Paris",
    "ALT": "Alanine aminotransferase",
    "ANC": "Absolute neutrophil count",
    "AST": "Aspartate aminotransferase",
    "BMI": "Body mass index",
    "BUN": "Blood urea nitrogen",
    "CNIL": "Commission nationale informatique et libertés",
    "COPD": "chronic obstructive pulmonary disease",
    "CPK": "Creatinine phosphokinase",
    "CPP": "comité de protection des personnes",
    "CRA": "Clinical Research Associates",
    "CRB": "Centre de Ressources Biologiques",
    "CRP": "C Reactive protein",
    "CRPV": "Centre Régional de Pharmacovigilance",
    "CTCAE": "Common Terminology Criteria for Adverse Events",
    "DRCI": "Délégation à la Recherche Clinique et à l’Innovation",
    "DSMB": "Data safety monitoring board",
    "DSUR": "Development Safety Update Report",
    "ECMO": "extra corporeal membrane oxygenation",
    "EMA": "European Medicine Agency",
    "ER": "emergency room",
    "eCRF": "electronic case report form",
    "GCP": "Good Clinical Practices",
    "Gamma-GT": "gamma glutamyl transpeptidase",
    "GP": "general practitioner",
    "HCSP": "Haut Conseil à la Santé Publique",
    "ICU": "intensive care unit",
    "ITT": "intent to treat",
    "IEAC": "independent endpoint adjudication comittee",
    "NIV": "non invasive ventilation",
    "PHRC": "programme hospitalier de recherche clinique",
    "PI": "principal investigator",
    "RTPCR": "reverse-transcription polymerase chain reaction",
    "RRT": "renal replacement therapy",
    "SpO2": "Peripheral oxygensaturationby pulse oxymeter",
    "SAE": "serious adverse event",
    "SBIM": "Service de Biostatistique et Information Médicale",
    "TMPRSS2": "cellular serine protease",
    "WHO": "World health organization"
  },
  "GREEN_protocole_signé_v4.0_20240424": {
    "ADA": "Anti-glenzocimab Drug Antibodies",
    "ANSM": "Agence Nationale de Sécurité des Médicaments et des Produits de santé",
    "CPP": "Comité de Protection des Personnes",
    "EVT": "Endovascular therapy",
    "IVT": "Intravenous thrombolysis",
    "MCA": "Middle Cerebral Artery",
    "MT": "mechanical thrombectomy",
    "MRI": "magnetic resonance imaging",
    "MRA": "magnetic resonance angiography",
    "AIS": "acute ischemic stroke",
    "LVO": "large vessel occlusion",
    "ICA": "intracranial internal carotid artery",
    "CTA": "CT angiography",
    "CTP": "Perfusion CT-scan",
    "DAPT": "dual anti-platelet therapy",
    "ICH": "IntraCranial Hemorrhages",
    "CCTAE": "common toxicity criteria",
    "AE": "adverse effect",
    "SAE": "serious adverse event",
    "SUSAR": "Suspected Unexpected Serious Adverse Reaction",
    "BRE": "Bleeding-Related Event",
    "TEAE": "Treatment Emergent Adverse Event",
    "tPA" :"tissue plasminogen activator"
  },
  "19DAE-RECORDS_protocole_v6_11052022_RECORDS_DRC": {
    "ADR": "Adverse Drug Reaction",
    "AE": "Adverse Event",
    "AGEPS": "Agence générale des équipements et produits de santé-APHP",
    "ANSM": "Agence nationale de sécurité du médicament et des produits de santé",
    "APHP": "Paris Public Hospital Assistance",
    "CMU": "Couverture Maladie Universelle",
    "CRF": "Case Report Form",
    "CRP": "C-reactive protein",
    "CTA": "Clinical Trial Application",
    "DSMC": "Data Safety Monitoring Committee",
    "DRCI": "Delegation of Clinical Research and Innovation",
    "eCRF": "Electronic Case Report Form",
    "EDC": "Electronic Data Capture",
    "ELISA": "Enzyme Linked ImmunoSorbent Assay",
    "ICU": "Intensive Care Unit",
    "IPDMA": "Individual Patient Data Meta-Analysis",
    "IRB": "Institutional Review Board",
    "MDW": "Monocyte distribution width",
    "DUSP-1": "Dual-Specificity Phosphatase 1",
    "HRQoL": "Health Related Quality of Life",
    "RCT": "Randomized Controlled Trial",
    "REB": "Research Ethics Board",
    "SADR": "Serious Adverse Drug Reaction",
    "SAE": "Serious Adverse Event",
    "SOFA": "score Sequential Organ Failure Assessment score",
    "SOFAscore": "Sequential Organ Failure Assessment score",
    "SUADR": "Serious Unexpected Adverse Drug Reaction",
    "SUSAR": "Suspected Unexpected Serious Adverse Reaction",
    "URC": "HUPIFO Paris Ile de France Ouest Clinical Research Unit",
    "WHO": "World Health Organization"
  }
}